Consistent with these data, FAM83A levels correlated positively with nuclear β-catenin (r=0.63; P<0.05) and p-Smad3 expression (r=0.77; P<0.05) in 10 freshly collected clinical pancreatic cancer samples, further suggesting FAM83A expression is clinically associated with Wnt/β-catenin and TGF-β/Smad pathway activation in pancreatic cancer (Supplementary Figure S3c). This evidence concerns the gene SMAD3 and pancreatic neoplasm.